STOCK TITAN

Jaguar Health Inc - JAGX STOCK NEWS

Welcome to our dedicated news page for Jaguar Health (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Jaguar Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Jaguar Health's position in the market.

Rhea-AI Summary
Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, announced the sponsorship of a Multinational Association of Supportive Care in Cancer (MASCC) webinar titled 'GI Toxicities from Cancer Therapies - Prevention and Management.' The webinar, scheduled for Monday, January 29, 2024, is aimed at addressing the quality of life of cancer patients. Napo's Vice President of Clinical Research & Medical Affairs, Dr. Allison Shrier, expressed the company's commitment to supporting cancer patients' dignity and quality of life.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
-
Rhea-AI Summary
Napo Pharmaceuticals (Napo) announced the release of the abstract for 'More Than a Diagnosis: A Quality of Life Survey for Individuals with a Diagnosis or History of Cancer' at the December 2023 San Antonio Breast Cancer Symposium. The survey, supported by Napo, aims to shed light on the challenges faced by individuals living with a cancer diagnosis. Stacey Tinianov, MPH, a member of the Jaguar/Napo Scientific Advisory Board, highlighted the importance of managing treatment side effects and the collaboration with patients and survivors in developing the survey. The survey revealed a decline in quality of life scores for respondents with a history of breast cancer, with physical and emotional well-being being top priorities. Fatigue, muscle/joint pain, and emotional distress were cited as primary concerns, with a significant percentage reporting severe emotional distress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
-
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) announced the renewal of Canalevia-CA1, the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive FDA approval. The drug is available from leading veterinary distributors in the U.S. until December 21, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.55%
Tags
fda approval
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) will present virtually on December 5, 2023 at the MedInvest Oncology Investor Conference. The company's founder, Lisa Conte, will discuss top line data for the pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
conferences
-
Rhea-AI Summary
Napo Pharmaceuticals (Napo) announced that the company has not yet received results from the GCP vendors supporting Napo's pivotal Phase 3 OnTarget trial. The trial is evaluating crofelemer, a plant-based prescription drug, for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. Lisa Conte, Jaguar Health's president and CEO, stated that the company remains blinded to study results at this time. The OnTarget trial's top line results are forthcoming, and the company's abstract outlining the trial's design has been accepted by the December 2023 San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.89%
Tags
clinical trial
-
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) reported a 5% increase in net revenue in Q3 2023 compared to Q2 2023. The company also provided updates on its phase 3 OnTarget trial of crofelemer for the preventative treatment of cancer therapy-related diarrhea. Top line results are expected before Thanksgiving. Jaguar will host an investor webcast on November 14th regarding Q3 2023 financials and company updates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.1%
Tags
earnings
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) Grants 7,500 RSUs to New Employee
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Napo Pharmaceuticals (Napo) Announces Acceptance of Quality of Life Survey Results for Presentation at San Antonio Breast Cancer Symposium (SABCS)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
none
-
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) received a 180-day grace period from Nasdaq to regain compliance with the $1.00 bid price requirement. The company's Phase 3 pivotal OnTarget trial of Mytesi for the preventative treatment of cancer therapy-related diarrhea is nearing completion, with top line results expected before Thanksgiving. Jaguar is also supporting investigator-initiated studies of crofelemer for rare disease indications, with results expected before the end of 2023 and in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.07%
Tags
none
Rhea-AI Summary
Jaguar Health, Inc. (NASDAQ:JAGX) to file Earnings Report on November 14, 2023 and host investor webcast. Also, hosting virtual educational webinar on rare intestinal failure diseases on November 8, 2023. Click here to register for both events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.07%
Tags
earnings
Jaguar Health Inc

Nasdaq:JAGX

JAGX Rankings

JAGX Stock Data

4.49M
40.68M
15.72%
2.43%
7.8%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Francisco

About JAGX

jaguar health, inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. our wholly-owned subsidiary, napo pharmaceuticals, inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. our mytesi® (crofelemer) product is approved by the u.s. fda for the symptomatic relief of noninfectious diarrhea in adults with hiv/aids on antiretroviral therapy. canalevia™ is our lead animal prescription drug candidate, intended for treatment of various forms of diarrhea in dogs. equilevia™ is jaguar’s non-prescription product for total gut health in equine athletes. to read our full social media policy, please visit https://jaguar.health/social-media-policy/